Seventure, BioGeneration lead €18.5m round for Citryll

Existing investors BrightGene, BOM Brabant Ventures and ModiQuest also took part.

Additionally, Citryll has been awarded an Innovation Credit from the Dutch government through its agency RVO of the Ministry of Economic Affairs and Climate Policy, set up to stimulate the development of high-potential innovations.

The company will use the proceeds for the further development of Citryll's CIT-013 drug, which has the potential to treat autoimmune disorders such as lupus, organ damage due to sepsis, asthma and thrombosis induced by neutrophil extracellular traps (NET). The programme is on track to reach the clinic in 2021.

Previous funding
In 2019, the company raised €15m in a series-A round led by BOM Brabant Ventures, BrightGene, Curie Capital and ModiQuest.

Company
Founded in 2015 and based in Oss, Citryll is a pharmaceutical company focused on the development and commercialisation of therapeutics that target NETosis and NETs. The company employs 10 staff, according to its LinkedIn page. 

People
Citryll – Helmuth van Es (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Benelux
• Healthcare
• Venture
• Netherlands
• Benelux
• Seventure (SPEF)
• healthcare